The death of a woman in a study combining Advaxis Inc.'s lead immunotherapy candidate, axalimogene filolisbac (axal), and Astrazeneca plc's Imfinzi (durvalumab) to treat two types of carcinoma has triggered an FDA clinical hold, halting further dosing and enrollment in the study. Although the final cause of death is still under investigation, a spokesperson for Advaxis told BioWorld that initial reports point to respiratory failure.